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Abstract
Targeted biopsy with multiparametric magnetic resonance imaging and hypoechoic lesions on transrectal ultrasound has been
implemented to increase prostate cancer detection rate.
We compared the detection abilities of systematic prostate biopsy, hypoechoic lesion-targeted biopsy (HL-TBx), and cognitive
magnetic resonance imaging-targeted biopsy (MRI-TBx) in patients with suspected prostate cancer. Between September 2014 and
August 2016, 193 patients with a prostate-specific antigen level of 3 to 10ng/mL underwent HL-TBx or MRI-TBx. In patients who
refused magnetic resonance imaging examination before prostate biopsy, HL-TBx was performed. We compared cancer detection
rates and pathologic outcomes between systematic prostate biopsy and HL-TBx or MRI-TBx.
The cancer detection rates for HL-TBx and MRI-TBx were 40.8% and 43.8%, respectively, without a significant difference
(P= .683). Of the 81 patients diagnosed with prostate cancer, most patients (77 patients, 95.1%) were diagnosed with prostate
cancer by systematic prostate biopsy. The detection ability for prostate cancer was significantly better for systematic prostate biopsy
than for HL-TBx or MRI-TBx (P< .001).
The detection abilities for clinically significant prostate cancer similar between HL-TBx and systematic prostate biopsy. Systematic
prostate biopsy alone should be recommended for detection prostate cancer in patients with a prostate-specific antigen10ng/mL.
Abbreviations: DRE = digital rectal examination, HL-TBX = hypoechoic lesion-targeted biopsy, IRB = institutional review board,
MRI-TBX = magnetic resonance imaging-targeted biopsy, PCa = prostate cancer, PSA = prostate-specific antigen, PV = prostate
volume, TRUS = transrectal ultrasound.
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1Key Points
 Hypoechoic lesion- and MRI-targeted biopsies were
inferior to systematic biopsy.
 Systematic prostate biopsy alone should be recommended
for detecting prostate cancer.
 Targeted biopsy adds little clinical value despite its greater
cost and time.1. Introduction
Transrectal ultrasound (TRUS)-guided systematic prostate
biopsy (SBx) of 12 cores is the standard biopsy approach
for men with suspected prostate cancer (PCa). However,
approximately 30% of men with clinically detectable PCa are
not diagnosed in the initial biopsy.[1] To raise cancer detection
rates, physicians could perform magnetic resonance imaging
(MRI)-based targeted biopsy (TBx) using multiparametric MRI
for guidance to areas suspicious of cancer.[2] However, MRI
has not significantly increased the accuracy of PCa risk
prediction and is not recommended in the setting of first
prostate biopsy.[3] Accordingly, we previously suggested the
use of hypoechoic lesions on TRUS to raise PCa detection
rates. Although hypoechoic lesions on TRUS are not an
indication for prostate biopsy, this method has been shown to
be effective.[4,5]
Table 1
Basic characteristics of the patients according to the biopsy
method.
HL-TBx MRI-TBx P-value
Number of patients 120 73
Age, yr 65.8 (59.5–73.2) 65.5 (60.2–70.7) .806
Previous PBx history (yes) 14 (11.7) 20 (27.4) .006
PSA (ng/mL) 5.44 (4.29–6.34) 6.14 (4.83–7.95) .015
Prostate volume (cc) 40.4 (29.7–49.8) 41.5 (31.1–56.3) .275
PSA density (ng/mL/cc) 0.14 (0.10–0.19) 0.15 (0.11–0.20) .292
Volume per core (cc/core) 2.94 (2.20–3.64) 2.73 (1.92–3.69) .179
Cancer detection 49 (40.8) 32 (43.8) .685
Patients with positive SBx 46 (93.9) 31 (96.9) .572
Patients with positive TBx 20 (40.8) 15 (46.9) .500
Data are shown as number (%) or median (interquartile range).
DRE=digital rectal examination, HL-TBx=hypoechoic lesion-targeted biopsy, MRI-TBx= cognitive
magnetic resonance imaging-targeted biopsy, PBx=prostate biopsy, PSA=prostate-specific antigen,
SBx= systematic prostate biopsy, TBx= targeted biopsy.
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sary biopsies, thereby decreasing post-procedural risk and pain
and, at the same time, increasing PCa detection rates. Thus, many
studies have focused on evaluating the efficacy of TBx using not
only MRI but also TRUS.[5] However, TBx cannot be performed
independently of SBx and should only be used as a supplementary
method under the assumption that it would raise the PCa
detection rate according to the National Comprehensive Cancer
Network guidelines.[4] Indeed, there is no consensus on when
TBx should be performed and on whether TBx is truly needed
when performing SBx. In an effort to help reach a consensus, we
performed SBx with TBx by TRUS hypoechoic lesion-targeted
biopsy (HL-TBx) and MRI-TBx and compared PCa detection
rates and pathologic outcomes (under the same numbers of cores
for HL-TBx and MRI-TBx) in patients with a prostate-specific
antigen (PSA) level of less than 10ng/mL.
2. Patients and methods
2.1. Study population and data collection
Institutional review board (IRB) approval was obtained (IRB
number: 3-2016-0151), and the requirement for informed
consent was waived owing to the retrospective nature of this
study. We reviewed the records of 205 patients with a PSA level
10ng/mL who underwent targeted prostate biopsy, including
both HL-TBx and MRI-TBx, at our institution from September
2014 to August 2016. Twelve patients with a prior diagnosis of
PCa were excluded. The remaining 193 patients were included in
the analysis.
Data on the following clinical and pathological features were
collected: age, history of previous prostate biopsy, prostate
volume (PV), PSA, PSA density, and clinical and pathological
disease staging according to the 7th edition of the American Joint
Committee on Cancer.
2.2. Indications and protocol for prostate biopsy
The indications for prostate biopsy were an elevated PSA level
(≥3ng/mL), a steadily increasing PSA level, or an abnormal
digital rectal examination (DRE). We explained the risks and
benefits of MRI to patients with suspected PCa. We performed
MRI in those who agreed to the evaluation. The MRI
examination included diffusion-weighted imaging, dynamic
contrast-enhanced imaging, and routine prostate MRI obtained
in 3 orthogonal planes (axial, sagittal, and coronal), and it was
performed using a 3.0-Tesla MRI scanner (Intera-Achieva 3.0T,
Phillips Medical System, Best, the Netherlands) equipped with a
phased-array coil (6-channel). Two b values (0–1000) were used,
and diffusion restriction was quantified using apparent diffusion
coefficient mapping. All images were interpreted by 2 uroradi-
ologists. If the conclusions of the 2 reviewers differed, they
discussed the findings and reached a consensus. In patients with
no visible lesions on MRI, an additional precise PSA follow up
was recommended instead of immediate prostate biopsy; these
patients were excluded in this study. In patients who refused the
MRI examination, HL-TBx was performed at hypoechoic lesions
on TRUS.
All prostate biopsies were performed by a single urologist with
over 150 cases of experience in MRI-TBx to reduce bias. For a
single patient, either HL-TBx or MRI-TBx was performed for 2
cores. After all TBx procedures, SBx with 12 cores was
performed. For HL-TBx, a hypoechoic lesion on TRUS was2defined as a region with hypoechogenicity relative to the
surrounding tissue. In HL-TBx, 2 hypoechoic lesions were
selected based on the operator’s discretion, and 1 core for each
hypoechoic lesion was obtained. For MRI-TBx, 2 cores for a
targeted lesion were obtained. If the target regions coincided with
systemic biopsy regions, target regions were given priority. The
volume per core ratio was calculated as the PV divided by the
number of biopsy cores. Significant PCa was defined as(1) a Gleason score ≥7,
(2) nonorgan-confinement (presence of extracapsular extension
and seminal vesicle or lymph node involvement), or
(3) a tumor volume ≥0.5 cc.[6,7]
2.3. Statistical analysis
Continuous variables are expressed as medians (interquartile
ranges), and categorical variables are reported as the number of
occurrences and frequency. Student t test and the Chi-square test
were used to evaluate differences in continuous and categorical
variables, respectively. Cancer detection rates were compared
between the examinations using the McNemar test. Univariate
andmultivariate logistic regression analyses were performed, and
variables that were significant in the univariate analysis were
included in the multivariate analysis. The HL-TBx andMRI-TBx
groups were matched on a 1:1 basis using propensity scores (41
patients in each group). Statistical analyses were performed using
SPSS, version 23.0 (SPSS Inc, Chicago, IL). All P-values <.05
were considered to indicate statistical significance.3. Results
The baseline characteristics of the 193 patients are presented in
Table 1. A total of 120 patients underwent HL-TBx, and 73
patients underwent MRI-TBx. The number of biopsy cores was
14 in both groups. A total of 81 patients (42.0%) was diagnosed
with PCa, and the detection rates did not significantly differ
between the HL-TBx and MRI-TBx groups (40.8% vs 43.8%,
P= .683). Of the patients diagnosed with PCa (81 patients), most
patients (77 patients, 95.1%) were diagnosed with PCa by SBx.
Multivariate logistic regression analysis showed age (odds
ratio [OR]=1.07 [95% confidence interval: 1.026–1.111],
P= .001) and PV (OR=0.95 [0.924–0.971], P< .001) to be
Table 2
Clinical features of patients according to the biopsy method after
propensity-score matching.
HL-TBx (n=41) MRI-TBx (n=41) P-value
Cancer detection 18 (43.9) 19 (46.3) .825
Age, yr 64.3 (59.9–66.9) 65.5 (61.8–71.9) .537
Previous PBx history (yes) 10 (24.4) 12 (29.3) .734
PSA (ng/mL) 6.15 (5.37–7.44) 6.42 (4.97–8.13) .423
Abnormal DRE 5 (12.2) 6 (14.6) .647
Prostate volume (cc) 39.6 (27.6–49.4) 42.9 (30.1–56.8) .256
PSA density (ng/mL/cc) 0.15 (0.12–0.22) 0.16 (0.11–0.23) .187
Volume per core (cc/core) 2.95 (2.06–3.74) 2.58 (2.04–3.75) .711
Patients with positive SBx 18/41 (43.9) 19/41 (46.3) .825
Lesions with positive TBx 25/82 (30.5) 36/82 (43.9) .016
Data are shown as number (%) or median (interquartile range).
DRE=digital rectal examination, HL-TBx=hypoechoic lesion-targeted biopsy, MRI-TBx=cognitive
magnetic resonance imaging-targeted biopsy, PBx=prostate biopsy, PSA=prostate-specific antigen,
SBx= systematic prostate biopsy, TBx= targeted biopsy.
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method was not a significant predictor of PCa detection. Cancer
detection and pathologic outcomes were further compared
between biopsy methods. Propensity-score matching was
performed using multivariate logistic regression on the basis of
the following covariates: age, previous prostate biopsy history,
PSA, DRE, and PV (Table 2). This analysis included 41 patients in
each group, and there were no group differences in cancer
detection rate (43.9% vs 46.3%, P= .825), age, previous prostate
biopsy history, PSA, abnormal findings on DRE, or PV. Although
there was no difference in the number of patients with a positive
SBx (18 vs 19, P= .825), the positive target lesion rate was higher
in the MRI-TBx group than in the HL-TBx group (30.5% vs
43.9%, P= .016).Table 4
Comparison of SBx with HL-TBx or MRI-TBx for the detection of clin
HL-TBx
No/insignificant cancer
(patients, n, %)
No/in
(
SBx
No/Insignificant cancer (patients, n, %) 94 (78.3%) 5 (4.
Clinically significant cancer (patients, n, %) 13 (10.8%) 8 (6.
P= .096 P< .
The P-value was calculated using the McNemar test.
HL-TBx=hypoechoic lesion-targeted biopsy, MRI-TBx= cognitive magnetic resonance imaging-targeted
Table 3
Comparison of SBx with HL-TBx or MRI-TBx for the detection of pro
HL-TBx
Negative for cancer
(patients, n, %)
Pos
(pa
SBx
Negative for cancer (patients, n, %) 71 (59.2%) 3 (2
Positive for cancer (patients, n, %) 29 (24.2%) 17
P< .001 P<
The P-value was calculated using the McNemar test.
HL-TBx=hypoechoic lesion-targeted biopsy, MRI-TBx= cognitive magnetic resonance imaging-targeted
3Subgroup analysis of individual biopsy methods was per-
formed to compare PCa detection rates between SBx and HL-
TBx. The positive rates of SBx and HL-TBx for PCa were 38.3%
(46/120 patients) and 16.7% (20/120 patients), respectively
(P< .001). In the comparison of PCa detection rates between SBx
and MRI-TBx, the positive rates for PCa were 42.5% (31/73
patients) and 20.5% (15/73 patients), respectively (P< .001). In
the TBx groups, 3 patients (6.1%) in the HL-TBx group and 1
patient (3.1%) in the MRI-TBx group were diagnosed with PCa
by TBx alone (Table 3).
In the comparison of detection rates for clinically significant
PCa between SBx and HL-TBx, the positive rates of SBx and HL-
TBx were 17.5% (21/120 patients) and 10.8% (13/120 patients),
respectively, without a significant difference (P= .453). However,
in the comparison between SBx andMRI-TBx, the detection rates
of SBx and MRI-TBx were 17.5% (21/120) and 9.1% (11/120),
respectively (P< .001). There were 5 patients (4.2%) with
insignificant SBx results but significant TBx results in the HL-TBx
group, but only 1 patient (1.4%) in the MRI-TBx group
(Table 4).4. Discussion
The present study is first to investigate whether SBx alone could
provide sufficient performance in the detection of PCa, without
the help of TBx, regardless of the biopsy methods, in a group of
patients with a PSA level 10ng/mL. For these patients,
performing only SBx was sufficient for primarily detecting PCa
with relatively good performance. TBx added little value in
increasing detection rates, despite its greater cost and time to
complete the procedure. If MRI has been performed, considering
MRI-TBx in addition to SBx would help increase detection rates,
although the difference in detection rates for SBx and MRI-TBxically significant prostate cancer.
TBx
HL-TBx
significant cancer
patients, n, %)
No/insignificant cancer
(patients, n, %)
No/insignificant cancer
(patients, n, %)
2%) 51 (69.9%) 1 (1.4%)
7%) 11 (15.1%) 10 (13.7%)
001
biopsy, SBx= systematic prostate biopsy.
state cancer.
TBx
MRI-TBx
itive for cancer
tients, n, %)
Negative for cancer
(patients, n, %)
Positive for cancer
(patients, n, %)
.5%) 41 (56.2%) 1 (1.4%)
(14.2%) 17 (23.3%) 14 (19.2%)
.001
biopsy, SBx= systematic prostate biopsy.
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ineffective in improving detection rates above those achievedwith
SBx in this study, although other studies we have performed
indicated that implementing quantitative values of hypoechoic
lesions would increase detection rates.[5] Accordingly, we
are planning to conduct a thorough cost-effectiveness analysis
of HL-TBx for detecting PCa.
We performed SBx with 12 cores and TBx with 2 cores in all
patients with a PSA level10ng/mL usingMRI-TBx or HL-TBx.
Only a few patients were not diagnosed with PCa by SBx;
however, many of the PCa cases were not detected by TBx. This
implies that the accuracy of accompanying imaging modalities
should be improved to increase the prediction accuracy of TBx.
Until then, SBx alone is suitable as a standard detection approach
for PCa, without the need for TBx. Regarding the imaging
modalities for TBx, we could not determine whether MRI or
TRUS was superior in the present study.
Imaging modalities, including MRI, have been implemented in
an attempt to increase PCa detection rates, and previous studies
have reported that overall and clinically significant PCa detection
rates are higher in SBx with MRI-TBx than in SBx alone.[8]
However, our results showed that SBx alone could detect PCa
overall with relatively good performance. Most of the PCa cases
(95.1%) were detected by SBx, and only a small number (4.9%)
were detected by TBx alone (Table 1).
While many studies have compared MRI-TBx with SBx, few
have compared detection rates between MRI-TBx and HL-TBx.
One study reported that the detection rates for HL-TBx andMRI-
TBx were 40.8% and 46.9%, respectively, without significant
differences and were comparable to the detection rate of initial
biopsy of approximately 30%.[1] Another study indicated that
approximately 30% to 35%ofmenwith a PSA level of 4 to 10ng/
mL are diagnosed with PCa.[4] In the present study, the detection
rates of 40.8% and 43.8% in the HL-TBx and MRI-TBx groups
were relatively higher than those reported in previous studies.
Although there was no difference in the overall detection rate
between the methods, propensity-score matched analysis
revealed that HL-TBx showed a lower positive target lesion rate
than MRI-TBx with significance. This implied that MRI-TBx is
more effective in detecting PCa than HL-TBx, and that HL-TBx
should not be considered as an option for TBx, as it adds little
value to SBx. Previous studies on HL-TBx have suggested that
SBx should be performed regardless of echogenicity,[9,10,11]
which is consistent with our results.
A previous study reported that patients with a hypoechoic
lesion on TRUS show higher PSA levels, Gleason scores, and
percentages of positive cores and that patients without
hypoechoic lesions have better outcomes than patients with
hypoechoic lesions.[12] Moreover, target lesions with hypoecho-
genicity on MRI-TRUS fusion biopsy yielded an increase in the
detection of higher-grade PCa, compared to that achieved with
the biopsy of MRI lesions alone.[13] Accordingly, hypoechoic
lesions on TRUS have been considered as target lesions in MRI-
TBx and set as additional targets. As such, we have focused on
using quantitative values of hypoechoic lesions in TRUS to
improve the accuracy and effectiveness of PCa detection ability
by HL-TBx.[5] We reported that the grayscale values of
hypoechoic lesions are significant predictive factors for PCa
and high-grade disease.[5] The present study reported similar
findings to those in our previous study regarding the efficacy of
HL-TBx. Herein, HL-TBx detected clinically significant PCa in 5
patients that was not detected by SBx. In detecting clinically4significant PCa, there was no difference between SBx and HL-
TBx, supporting the efficacy of HL-TBx, if performed properly.
We believe that we should not abandon HL-TBx and that
additional research on the grayscale values of hypoechoic lesions
would provide effective information on PCa.
The present study reaffirmed the efficacy of MRI-TBx
described in recent studies.[14,15,16] One patient was diagnosed
by MRI-TBx, but the diagnosis was missed by SBx. Moreover, 1
patient was diagnosed with clinically significant PCa by MRI-
TBx, but, again, the diagnosis was missed by SBx. A recent
multicenter clinical trial demonstrated that MRI-TBx was
superior to standard SBx.[14] Similarly, our results showed the
effectiveness of MRI in detecting PCa that, in some cases, SBx
could not detect. The study by Kasivisvanthan and colleagues
enrolled participants with a PSA less than 20ng/mL, whereas our
study enrolled patients with PSA less than 10ng/mL, which may
explain why the effectiveness of MRI was underestimated in our
study, compared with other studies.[14] Regarding targeting
modalities, lesions positive on TBx were significantly more
frequent on MRI-TBx than on HL-TBx after propensity-score
matching. However, HL-TBx also showed good performance in
detecting clinically significant PCa in 5 patients in whom PCa
detection was missed by SBx, and there was no statistically
significant difference between SBx and HL-TBx in detecting
clinically significant PCa.
We should not depend solely on TBx for detecting PCa, and
TBx cannot totally replace SBx due to the underestimation of PCa
by MRI. A recent study reported that MRI underestimated
histologically determined tumor boundaries in 46 tumor lesions
from 33 patients who underwent 3.0-Tesla MRI and prostatec-
tomy.[17] Moreover, among 1895 patients who underwent
radical prostatectomy at our institution, 242 (12.8%) patients
had negative findings on MRI.[18] Therefore, until imaging
modalities for PCa advance further, clinicians should not solely
depend on MRI and MRI-TBx and should consider SBx.
The present study has several limitations. First, the present
study was not designed as a randomized controlled study with
high-level evidence. Individual patient factors, such as educa-
tional status and economical and social backgrounds, might
affect clinical decision-making onwhether or not to performMRI
examination. Nevertheless, we believe that this variation may
reflect actual clinical practice. Second, the prostate imaging
reporting and data system (PI-RADS) version was changed
during the study period. We could not uniformly apply the same
version due to the limitation of the retrospective study design, and
analyzing PI-RADS would produce different results in the
detection rate of lesions according to PI-RADS score. Therefore,
we analyzed the detection rate of suspicious lesions and did not
compare the detection rate of MRI-TBx in the present study with
that in previous studies. Third, we included patients with
previous biopsy history to increase the size of the study
population. However, we could not document the time between
previous biopsy, since most of the patients with previous biopsy
history visited our institution after the first prostate biopsy at
other hospitals and since the exact medical records were missing.
Finally, this retrospective study was based on a single operator’s
experience. Hence, our results might not be applicable to other
HL-TBx series. Considering that the selection of hypoechoic
lesions may differ according to the operator, a larger series or a
multi-institutional study may address this limitation in the future.
In conclusion, SBx alone should be primarily recommended for
the detection of PCa. Although TBx would help increase the PCa
Park et al. Medicine (2019) 98:51 www.md-journal.comdetection rate, it adds little value considering its cost and time.
We believe that the development of more sophisticated methods
for the quantitation of hypoechoic lesions would result in a more
affordable PCa diagnostic tool.
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